High-dose therapy and autologous stem cell transplant does not result in long-term disease-free survival in patients with reccurent chemotherapy-sensitive ALK-negative anaplastic large-cell lymphoma

Bone Marrow Transplantation

Volumn 33, Issue 6, 2004, Pages 635-638

  Zamkoff, K W ^a,d   Matulis, M D ^a   Mehta, A C ^b   Beaty, M W ^a   Hutchison, R E ^c   Gentile, T C ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^c State University of New York Upstate Medical University: College of Medicine   (United States)

^d STONY BROOK UNIVERSITY   (United States)

Author keywords

Autologous stem cell transplant; Recurrent ALK negative ALCL

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; BUSULFAN; CARMUSTINE; CD15 ANTIGEN; CD30 ANTIGEN; CYCLOPHOSPHAMIDE; ETOPOSIDE; THIOTEPA;

ADULT; AGED; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SENSITIVITY; FEMALE; FOLLOW UP; HUMAN; LARGE CELL LYMPHOMA; MALE; NONHODGKIN LYMPHOMA; NULL CELL; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; REVIEW; SCORING SYSTEM; T CELL LYMPHOMA; UNITED STATES;

DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, LARGE-CELL; MALE; PROTEIN-TYROSINE KINASES; RECEPTOR PROTEIN-TYROSINE KINASES; RECURRENCE; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS;

EID: 1842483136     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704392     Document Type: Review

References (21)

1. Stein H, Foss HD, Durkop H et al. CD30 + anaplastic large cell lymphoma: A review of its histopathologic, genetic and clinical features. Blood 2000; 96: 3681-3695.
2. Falini B. Anaplastic large cell lymphoma: Pathological, molecular and clinical features. Br J Haematol 2001; 114: 741-760.
3. Pulford K, Lamant L, Morris SW et al. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood 1997; 89: 1394-1404.
4. Benharroch D, Meguerian-Bedoyan Z, Lamant L et al. ALK-positive lymphoma: A single disease with a broad spectrum of morphology. Blood 1998; 91: 2076-2084.
5. Falini B, Pileri S, Zinzani PL et al. ALK + lymphoma: clinicopathological findings and outcome. Blood 1999; 93: 2697-2706.
6. Gascoyne RD, Aoun P, Wu D et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 1999; 93: 3913-3921.
7. Fanin R, Ruiz de Elvira MC, Sperotto A et al. Autologous stem cell transplantation for T and null cell CD30 + anaplastic large cell lymphoma: Analysis of 64 adult and pediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1999; 23: 437-442.
8. Blystad AK, Enblad G, Kvaloy S et al. High dose therapy with autologous stem cell transplantation in patients with pheripheral T cell lymphomas. Bone Marrow Transplant 2001; 27: 711-716.
9. Rodriguez J, Munsell M, Yazji S et al. Impact of high dose chemotherapy on peripheral T cell lymphomas. J Clin Oncol 2001; 19: 3766-3770.
10. Delsol G, Ralkiaer E, Stein H et al. Anaplastic large cell lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissue. IARC Press: Lyon, France, 2001, pp 230-235.
11. Shipp MA, Harrington DP, Anderson JR et al. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-994.
12. Ansell SM, Habermann TM, Witzig TE et al. Predictive capacity of international prognostic factor index in patients with peripheral T cell lymphoma. J Clin Oncol 1997; 15: 2296-2301.
13. Haioun C, Lepage E, Gisselbrecht C et al. Survival benefit of high dose therapy in poor risk aggressive non-Hodgkin's lymphomas: Final analysis of the prospective LNH 87-2 protocol - A Group d'Etude des Lymphomes de l'Adulte study. J Clin Oncol 2000; 16: 3025-3030.
14. Deconinck E, Lamy T, Foussard C et al. Autologous stem cell transplantation for anaplastic large cell lymphomas: Results of a prospective trial. Br J Haematol 2000; 109: 736-742.
15. Mounier N, Simon D, Haioun C et al. Impact of high dose chemotherapy on peripheral T cell lymphoma. J Clin Oncol 2002; 20: 1426-1427, (letter).
16. Gisselbrecht C, Gaulard P, Lepage E et al. Prognostic significance of T cell phenotype in aggressive non-Hodgkin's lymphomas. Blood 1998; 92: 76-82.
17. Rassidakis GZ, Sarris AH, Herling M et al. Differential expression of BCL-2 family proteins in ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null-cell lineage. Am J Pathol 2001; 159: 527-535.
18. ten Berge RL, Meijer CJLM, Dukers DF et al. Expression levels of apoptosis related proteins predict clinical outcome in anaplastic large cell lymphoma. Blood 2002; 99: 4540-4546.
19. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus Rituximab compared with CHOP alone in elderly patients with diffuse large cell B cell lymphoma. N Engl J Med 2002; 346: 235-242.
20. Delsol G, Saati TA, Gatter KC et al. Coexpression of epithelial membrane antigen (EMA), Ki-1 and interleukin-2 receptor by anaplastic large cell lymphomas. Diagnostic value in so-called malignant histiocytosis. Am J Pathol 1988; 130: 59-70.
21. Janik JE, Morris JC, Pittaluga S et al. Serum soluble IL-2 receptor levels are elevated in patients with anaplastic large cell lymphoma (ALCL). Blood 2002; 100: 2505a (abstract).